KindlyMD (NASDAQ:NAKA) CEO David Bailey Buys 104,833 Shares of Stock

KindlyMD, Inc. (NASDAQ:NAKA) CEO David Bailey acquired 104,833 shares of KindlyMD stock in a transaction on Wednesday, May 27th. The shares were purchased at an average price of $4.84 per share, for a total transaction of $507,391.72. Following the completion of the acquisition, the chief executive officer directly owned 3,120,361 shares in the company, valued at $15,102,547.24. This trade represents a 3.48% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

KindlyMD Stock Up 3.7%

NAKA opened at $5.60 on Friday. The stock’s fifty day moving average is $8.21 and its two-hundred day moving average is $13.07. The company has a market capitalization of $97.44 million, a P/E ratio of -0.13 and a beta of 17.12. KindlyMD, Inc. has a 52 week low of $4.50 and a 52 week high of $995.60.

KindlyMD (NASDAQ:NAKA) last released its quarterly earnings data on Wednesday, May 13th. The company reported ($15.20) EPS for the quarter. The firm had revenue of $2.68 million for the quarter. KindlyMD had a negative return on equity of 81.32% and a negative net margin of 7,397.12%. Equities analysts anticipate that KindlyMD, Inc. will post -16.8 earnings per share for the current year.

Wall Street Analyst Weigh In

Several analysts have issued reports on the company. B. Riley Financial dropped their target price on KindlyMD from $40.00 to $20.00 and set a “buy” rating on the stock in a research report on Monday, February 23rd. Wall Street Zen raised KindlyMD to a “sell” rating in a research report on Saturday, May 23rd. Maxim Group dropped their target price on KindlyMD from $60.00 to $30.00 and set a “buy” rating on the stock in a research report on Monday, April 6th. TD Cowen assumed coverage on KindlyMD in a research report on Friday, April 10th. They set a “buy” rating and a $40.00 target price on the stock. Finally, Weiss Ratings raised KindlyMD from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, May 11th. Three analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $30.00.

Institutional Trading of KindlyMD

A number of institutional investors have recently made changes to their positions in NAKA. Alyeska Investment Group L.P. acquired a new stake in shares of KindlyMD in the 4th quarter worth $8,993,000. ParaFi Capital LP acquired a new stake in shares of KindlyMD in the 3rd quarter worth $443,055,000. Hunting Hill Global Capital LLC acquired a new stake in shares of KindlyMD in the 4th quarter worth $4,672,000. RK Capital Management LLC FL acquired a new stake in shares of KindlyMD in the 3rd quarter worth $239,052,000. Finally, Yorkville Advisors Global LP acquired a new stake in shares of KindlyMD in the 3rd quarter worth $231,942,000.

About KindlyMD

Kindly MD, Inc (“KindlyMD” or “Kindly”) is a Utah company formed in 2019. KindlyMD is a healthcare data company, focused on holistic pain management and reducing the impact of the opioid epidemic. KindlyMD offers direct health care to patients integrating prescription medicine and behavioral health services to reduce opioid use in the chronic pain patient population. Kindly believes these methods will help prevent and reduce addiction and dependency on opiates. Our specialty outpatient clinical services are offered on a fee-for-service basis.